Loading company…
Matterhorn Biosciences AG of Basel, Switzerland develops T-cell receptor therapies that target the MR1 molecule in cancer.
Based in Basel, Switzerland, Matterhorn Biosciences AG develops T-cell receptor therapies that help patients with cancer by targeting the MR1 molecule. The company is listed at Series B stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in